Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1361-1371

  Graham, Michael R ^a   Evans, Peter ^b   Davies, Bruce ^a   Baker, Julien S ^a  

^a UNIVERSITY OF GLAMORGAN   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

Arterial pulse; Arterial stiffness; Growth hormone; Insulin like growth factor; Physiology; Wave velocity

Indexed keywords

C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; GROWTH HORMONE RECEPTOR; HOMOCYSTEINE; HUMAN GROWTH HORMONE; INTERLEUKIN 6; NITRIC OXIDE; PEGVISOMANT; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ABNORMAL SENSATION; ACROMEGALY; ADENOHYPOPHYSIS; AGING; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTHRALGIA; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MASS; BRAIN PSEUDOTUMOR; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR DISEASE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY PERFUSSION PRESSURE; DISEASE MARKER; DRUG INDICATION; DRUG INDUCED HEADACHE; EDEMA; ENCEPHALOCELE; ENDOTHELIAL DYSFUNCTION; EXERCISE; GENE EXPRESSION; GROWTH HORMONE DEFICIENCY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE STRUCTURE; HUMAN; HYPERTENSION; INFLAMMATION; JOINT EFFUSION; MORTALITY; MYALGIA; OXIDATIVE STRESS; PULSE PRESSURE; PULSE WAVE; REVIEW; SIDE EFFECT; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE; TINNITUS; VASODILATATION; WATER RETENTION; WEIGHT GAIN;

ACROMEGALY; AGE FACTORS; AGING; AMINO ACID SEQUENCE; ANIMALS; ARTERIES; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; ELASTICITY; EXERCISE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR SEQUENCE DATA; PULSATILE FLOW; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 60249085059     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Abdu TA, Elhadd TA, Akber M, et al. 2001. Plasma homocysteine is not a major risk factor for vascular disease in growth hormone deficient adults. Clin Endocrinol (Oxf), 55:635-8.
2. Amato G, Carella C, Fazio S, et al. 1993. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab, 77:1671-6.
3. Argetsinger LS, Campbell GS, Yang X, et al. 1993. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell, 74:237-44.
4. Asmar R, Benetos A, Topouchian J, et al. 1995. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension, 26:485-90.
5. Attanasio AF, Lamberts SW, Matranga AM, et al. 1997. Adult growth hormone-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab, 82:82-8.
6. Avolio AP, Chen SG, Wang RP, et al. 1983. Effects of ageing on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation, 68:50-8.
7. Avolio A, Jones D, Tafazzoli-Shadpour M. 1998. Quantification of alterations in structure and function of elastin in the arterial media. Hypertension, 32:170-5.
8. Balkestein EJ, Staessen JA, Wang JG, et al. 2001. Carotid and femoral artery stiffness in relation to three candidate genes in a white population. Hypertension, 38:1190-7.
9. Bank AJ, Wang H, Holte JE, et al. 1996. Contribution of collagen, elastin, and smooth muscle to in vivo human brachial artery wall stress and elastic modulus. Circulation, 94:3263-70.
10. Bank AJ, Klaiser DR, Rajala S, et al. 1999. In vivo human brachial artery elastic mechanics: effects of smooth muscle relaxation. Circulation, 100:41-7.
11. Baumann G. 1991. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev, 12:424-9.
12. Bazan NG. 2005. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol, 15:159-66.
13. Benetos A, Adamopoulos C, Bureau JM, et al. 2002. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation, 105:1202-7.
14. Bengtsson BA, Eden S, Lonn L, et al. 1993. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab, 76:309-17.
15. Berenson GS, Wattigney WA, Tracy RE, et al. 1992. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol, 70:851-8.
16. Bertovic DA, Waddell TK, Gatzka CD, et al. 1999. Muscular strength training is associated with low arterial compliance and high pulse pressure. Hypertension, 33:1385-91.
17. Beshyah SA, Freemantle C, Shahi M, et al. 1995. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf), 42:73-84.
18. Binnerts A, Swart GR, Wilson JHP, et al. 1992. The effect of growth hormone administration in growth hormone-deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as body composition. Clin Endocrinol, 37:79-87.
19. Blacher J, Asmar R, Djane S, et al. 1999a. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension, 33:1111-7.
20. Blacher J, Guerin AP, Pannier B, et al. 1999b. Impact of aortic stiffness on survival in end-stage renal disease. Circulation, 99:2434-9.
21. Black MM, Shuster S, Bottoms E. 1972. Skin collagen and thickness in acromegaly and hypopituitarism. Clin Endocrinol, 1:259-63.
22. Boutouyrie P, Tropeano AI, Asmar R, et al. 2002. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension, 39:10-5.
23. Bramwell JC, Hill AV. 1922. The velocity of the pulse wave in man. Proc R Soc Lond B Biol Sci, 93:298-306.
24. Bramwell JC, Hill AV, McSwiney BA. 1923. The velocity of the pulse wave in man in relation to age as measured by the hot wire sphygmograph. Heart, 10:233-55.
25. Brinton TJ, Kailasam MT, Wu RA, et al. 1996. Arterial compliance by cuff sphygmomanometer; Application to hypertension and early changes in subjects at genetic risk. Hypertension, 28:599-603.
26. British National Formulary. 2008. A joint publication of the British Medical Association and the Royal Pharmaceutical Society of Great Britain. BMJ Group and RPS Publishing [online]. Accessed Jan 18, 2008. URL: http://www.bnf.org.uk/.
27. Brown RJ, Adams JJ, Pelekanos RA, et al. 2005. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol, 12:814-21.
28. Busse R, Pohl U. 1993. Fluid shear-stress-dependent stimulation of endothelial cell autacoid release: mechanisms and significance for the control of vascular tone. In: Frangos JA, Ives CL (eds). Physical Forces and the Mammalian Cell. Orlando, FL: Academic Press, p. 223-48.
29. Bunevicius R, Kazanavicius K, Zalinkevicius R, et al. 1999. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med, 340:424-9.
30. Ceda GP, Dall'Aglio E, Maggio M, et al. 2005. Clinical implications of the reduced activity of the GH-IGF-I axis in older men. J Endocrinol Invest, 28 96-100.
31. Cocks TM, Angus JA, Campbell JH, et al. 1985. Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J Cell Physiol, 123:310-20.
32. Cohn JN, Finkelstein S, McVeigh G, et al. 1995. Non-invasive pulse wave analysis for the early detection of vascular disease. Hypertension, 26:503-8.
33. Crist DM, Kraner JC. 1990. Supplemental growth hormone increases the tumor cytotoxic activity of natural killer cells in healthy adults with normal growth hormone secretion. Metabolism, 39:1320-4.
34. Cuneo RC, Salomon F, Wiles CM, Sonksen PH. 1990. Skeletal muscle performance in adults with growth hormone-deficiency. Hormone Res, 33:55-60.
35. Cuneo RC, Salomon F, Wiles CM, et al. 1991a. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol, 70:688-94.
36. Cuneo RC, Salomon F, Wiles CM, et al. 1991b. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol, 70:695-700.
37. Cuneo RC, Salomon F, Wilmshurst P, et al. 1991c. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci (Lond), 81:587-92.
38. Cuneo RC, Salomon F, Wiles CM, et al. 1993. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone-deficiency. J Clin Endocrinol Metab, 42:1519-23.
39. Danesh J, Wheeler JG, Hirschfield GM, et al. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 350:1387-97.
40. De Boer H, Blok GJ, Voerman HJ, et al. 1994. Serum lipid levels in growth hormone-deficient men. J Clin Endocrinol Metab, 43:199-203.
41. Eichinger S, Stumpflen A, Hirschl M, et al. 1998. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost, 80:566-9.
42. Evans LM, Davies JS, Anderson RA, et al. 2000. The effect of GH replacement on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol, 142:254-62.
43. Evans LM, Davies JS, Goodfellow J, et al. 1999. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol, 50:457-64.
44. Ferrier KE, Waddell TK, Gatzka CD, et al. 2001. Aerobic exercise training does not modify large-artery compliance in isolated systolic hypertension. Hypertension, 38:222-6.
45. Ferrier KE, Muhlmann MH, Baguet JP, et al. 2002. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol, 39:1020-5.
46. Förstermann U, Nakane M, Tracey WR, et al. 1993. Isoforms of nitric oxide synthase: functions in the cardiovascular system. Eur Heart J, 14:10-5.
47. Fowelin J, Attvall S, Lager I, et al. 1993. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metab Clin Exper, 42:1443-7.
48. Furchgott RF. 1984. The role of endothelium in the responses of vascular smooth muscle to drugs. Ann Rev Pharmacol Toxicol, 24:175-97.
49. Giannattasio C, Cattaneo BM, Mangoni AA, et al. 1992. Changes in arterial compliance induced by physical training in hammer-throwers. J Hypertens, 10:53-5.
50. Giannattasio C, Vincenti A, Failla M, et al. 2003. Effects of heart rate changes on arterial distensibility in humans. Hypertension, 42:253-6.
51. Greenfield JC, Patel DJ. 1962. Relation between pressure and diameter in the ascending aorta of man. Circ Res, 10:778-81.
52. Greig CA, Hameed M, Young A, et al. 2006. Skeletal muscle IGF-1 isoform expression in healthy women after isometric exercise. Growth Horm IGF Res, 16:373-6.
53. Guerin AP, Blacher J, Pannier B, et al. 2001. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation, 103:987-92.
54. Hallock P, Benson IC. 1937. Studies on the elastic properties of human isolated aorta. J Clin Invest, 16:595-602.
55. Hew FL, Koschmann M, Christopher M, et al. 1996. Insulin resistance in growth hormone-deficient adults: defects in glucose utililization and glycogen synthase activity. J Clin Endocrinol Metab, 81:555-64.
56. Hoffman DM, Crampton I, Sernia C. 1996. Short term growth hormone (GH) treatment of GH deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab, 81:1123-8.
57. Holmes SJ, Economou G, Whitehouse RW, et al. 1994. Reduced bone mineral density in patients with growth hormone deficiency. J Clin Endocrinol Metab, 78:669-74.
58. Hussain MA, Schmitz O, Mengel A, et al. 1993. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest, 92:2249-56.
59. Iranmanesh A, Lizarralde G, Velduis JD. 1991. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab, 73:1081-8.
60. Joannides R, Richard V, Haefeli WE, et al. 1997. Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension, 30:1465-70.
61. Kaufman JM, Taelman P, Vermeuelen A, et al. 1992. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary insufficiencies of childhood onset. J Clin Endocrinol Metab, 74:118-23.
62. Kelly RP, Millasseau SC, Ritter JM, et al. 2001. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension, 37:1429-33.
63. Kingwell BA, Cameron JD, Gillies KJ, et al. 1995. Arterial compliance may influence baroreflex function in athletes and hypertensives. Am J Physiol, 268:411-8.
64. Kingwell BA, Berry KL, Cameron JD, et al. 1997a. Arterial compliance increases after moderate-intensity cycling. Am J Physiol, 273:2186-91.
65. Kingwell BA, Sherrard B, Jennings GL, et al. 1997b. Four weeks of cycle training increases basal production of nitric oxide from the forearm. Am J Physiol, 272:1070-7.
66. Kinlay S, Creager MA, Fukumoto M, et al. 2001. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension, 38:1049-53.
67. Kroeker EJ, Wood EH. 1955. Comparison of simultaneously recorded central and peripheral arterial pressure pulses during rest, exercise and tilted position in man. Circ Res, 3:623-32.
68. Lajemi M, Gautier S, Poirier O, et al. 2001a. Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives. Am J Hypertens, 14:755-60.
69. Lajemi M, Labat C, Gautier S, et al. 2001b. Angiotensin II type I receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens, 19:407-13.
70. Lantelme P, Mestre C, Lievre M, et al. 2002. Heart rate. An important confounder of pulse wave velocity assessment. Hypertension, 39:1083-7.
71. Laogun AA, Gosling RG. 1982. In vivo arterial compliance in man. Clin Phys Physiol Meas, 3:201-12.
72. Laurent S, Boutouyrie P, Asmar R, et al. 2001. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension, 37:1236-41.
73. Lehmann ED, Watts GF, Gosling RG. 1992a. Aortic distensibility and hypercholesterolaemia. Lancet, 340:1171-2.
74. Lehmann ED, Gosling RG, Sonksen PH. 1992b. Arterial wall compliance in diabetes. Diabet Med, 9:114-9.
75. Lehmann ED, Hopkins KD, Rawesh A, et al. 1998. Relation between number of cardiovascular risk factors/events and non-invasive Doppler ultrasound assessments of aortic compliance. Hypertension, 32:565-9.
76. Lehmann ED. 1999. Non-invasive measurements of aortic stiffness: methodological considerations. Pathol Biol (Paris). 47:716-30.
77. Leinninger GM, Backus C, Uhler MD, et al. 2004. Phosphatidylinositol 3-kinase and Akt effectots mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J, 18:1544-6.
78. Leonsson M, Hulthe J, Johannsson G, et al. 2003. Increased interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness. Clin Endocrinol, (Oxf). 59:242-50.
79. Le Roith D, Scavo L, Butler A. 2001. What is the role of circulating IGF-I? Trends Endocrinol Metab, 12:48-52.
80. Lilien MR, Schroder CH, Levtchenko EN, et al. 2004. Growth hormone therapy influences endothelial function in children with renal failure. Pediatr Nephrol, 19:785-9.
81. Linseman DA, Phelps RA, Bouchard RJ, et al. 2002. Insulin-like growth factor-I blocks Bcl-2 interacting mediator of cell death (Bim) induction and intrinsic death signaling in cerebellar granule neurons. J Neurosci, 22:9287-97.
82. Liu H, Bravata DM, Olkin I, et al. 2007. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med, 16:104-15.
83. Malozowski S, Tanner LA, Wysowski D, et al. 1993. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med, 329:665-6.
84. Mauras N, Haymond MW. 2005. Are the metabolic effects of GH and IGF-I separable. Growth Horm and IGF Res, 15:19-27.
85. Mauras N, Attie KM, Reiter EO, et al. 2000. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab, 85:3653-60.
86. McLeod AL, Uren NG, Wilkinson IB, et al. 2004. Non-invasive measures of pulse wave velocity correlate with coronary arterial plaque load in humans. J Hypertens, 22:363-8.
87. Mealy K, Barry M, O'Mahony L, et al. 1998. Effects of human recombinant growth hormone (rhGH) on inflammatory responses in patients undergoing abdominal sortie aneurysm repair. Intensive Care Med, 24:128-31.
88. Meaume S, Benetos A, Henry OF, et al. 2001. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol, 21:2046-50.
89. Medley TL, Cole TJ, Gatzka CD, et al. 2002. Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease. Circulation, 105:810-5.
90. Melmed S. 2006. Medical progress: Acromegaly. N Engl J Med, 14:2558-73.
91. Meredith IT, Currie KE, Anderson TJ, et al. 1996. Post ischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol, 270:1435-40.
92. Milani D, Carmichael JD, Welkowitz J, et al. 2004. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab, 89:2271-4.
93. Miyachi M, Donato AJ, Yamamoto K, et al. 2003. Greater age-related reductions in central arterial compliance in resistance-trained men. Hypertension, 41:130-5.
94. Miyachi M, Kawano H, Sugawara J, et al. 2004. Unfavourable effects of resistance training on central arterial compliance. A randomized intervention study. Circulation, 110:2858-63.
95. Mohiaddin RH, Underwood SR, Bogren HG, et al. 1989. Regional aortic compliance studied by magnetic resonance imaging: the effects of age, training and coronary artery disease. Br Heart J, 62:90-6.
96. Moncada S, Palmer RMJ, Higgs EA. 1991. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev, 43:109-42.
97. Mukherjee PK, Marcheselli VL, Serhan CN, et al. 2004. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A, 101:8491-6.
98. Muller AF, Leebeek FW, Janssen JA, et al. 2001. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency. J Clin Endocrinol Metab, 86:5165-71.
99. Naka KK, Tweddel AC, Parthimos D, et al. 2003. Arterial distensibility: acute changes following dynamic exercise in normal subjects. Am J Physiol Heart Circ Physiol, 284:970-8.
100. Napoli R, Guardasole V, Matarazzo M, et al. 2002. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol, 39:90-5.
101. Newby AC, Henderson AH. 1990. Stimulus-secretion coupling in vascular endothelial cells. Ann Rev Physiol, 52:661-74.
102. [NICE] The National Institute for Health and Clinical Excellence. 2003. The National Institute for Health and Clinical Excellence [online]. Published by the Health Development Agency. Accessed Jan 18, 2008. URL: http://www.nice.org.uk.
103. Nichols WW, O'Rourke MF. 1998. Wave reflections. In: McDonald's Blood Flow in Arteries: Theoretical, Experimental and Critical Principles. London: Edward Arnold.
104. O'Halloran DJ, Tsatsoulis A, Whitehouse RW, et al. 1993. Increased bone density after recombinant human growth hormone therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab, 76:1344-8.
105. Oliver JJ, Webb DJ. 2003. Non-invasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol, 23:554-66.
106. O'Neal DN, Kalfas A, Dunning PL, et al. 1994. The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab, 79:975-83.
107. O'Neal D, Few FL, Sikaris K, et al. 1996. Low density lipoprotein particle size in hypopituitary adults receiving conventional growth hormone replacement therapy. J Clin Endocrinol Metab, 81:2448-54.
108. O'Reilly KE, Rojo F, She QB, et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res, 66:1500-8.
109. O'Rourke MF. 1992. Arterial mechanics and wave reflection with antihypertensive therapy. J Hypertens Suppl, 10:43-9.
110. O'Rourke MF. 1999. Wave travel and reflection in the arterial system. J Hypertens, 17:45-7.
111. O'Rourke MF, Pauca A, Jiang XJ. 2001. Pulse wave analysis. Br J Clin Pharm, 51:507-22.
112. O'Rourke MF, Staessen JA, Vlachopoulos C, et al. 2002. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens, 15:426-44.
113. Pfeifer M, Verhovec M, Zizek B, et al. 1999. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab, 84:453-7.
114. Pohl U, Holtz J, Busse R, et al. 1986. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension, 8:37-47.
115. Ramsey MW, Goodfellow J, Jones CJH, et al. 1995. Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation, 92:3212-9.
116. Ridker PM, Rifai N, Rose L, et al. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 347:1557-65.
117. Riley WA, Freedman DS, Higgs NA, et al. 1986. Decreased arterial elasticity associated with cardiovascular disease risk factors in the young. The Bogalusa Heart Study. Arteriosclerosis, 6:378-86.
118. Rosen T, Eden S, Larson G, et al. 1993. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol, 129:195-200.
119. Rosen T, Wiren L, Wilhelmsen L, et al. 1994. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol, 40:111-6.
120. Rowell LB, Brengelmann GL, Blackmon JR, et al. 1968. Disparities between aortic and peripheral pulse pressures induced by upright exercise and vasomotor changes in man. Circulation, 37:954-64.
121. Russell-Jones DL, Weissberger AJ, Bowes SB, et al. 1993. The effects of growth hormone on protein metabolism in adult growth hormone-deficient patients. Clin Endocrinol, 38:427-31.
122. Safar ME, Blacher J, Pannier B, et al. 2002. Central pulse pressure and mortality in end-stage renal disease. Hypertension, 39:735-8.
123. Salomon F, Cuneo RC, Hesp R, et al. 1989. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med, 321:1797-803.
124. Sattar N, Gaw A, Scherbakova O, et al. 2003. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108:414-9.
125. Sesmilo G, Biller BM, Llevadot J, et al. 2000. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med, 133:111-22.
126. Sesmilo G, Fairfield WP, Katznelson L, et al. 2002. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab, 87:1692-9.
127. Smith JC, Evans LM, Wilkinson I, et al. 2002. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol, 56:493-501.
128. Smith JC, Lane H, Davies N, et al. 2003. The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab, 88:2556-61.
129. Snel YE, Doerga ME, Brummer RM, et al. 1995. Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in GHD adults. Effect of growth hormone replacement. Arterioscler Thromb Vasc Biol, 15:1543-8.
130. Stabler B, Turner JR, Girdler SS, et al. 1992. Reactivity to stress and psychological adjustment in adults with pituitary insufficiency. Clin Endocrinol, 6:467-73.
131. Stehouwer CD, Jakobs C. 1998. Abnormalities of vascular function in hyperhomocysteinaemia: relationship to atherothrombotic disease. Eur J Pediatr, 157:107-11.
132. Stewart AD, Millasseau SC, Kearney MT, et al. 2003. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension, 42:915-8.
133. Sutton-Tyrrell K, Mackey RH, Holubkov R, et al. 2001. Measurement variation of aortic pulse wave velocity in the elderly. Am J Hypertens, 14:463-8.
134. Tomiyama H, Yamashina A, Arai T, et al. 2003. Influences of age and gender on results of non-invasive brachial-ankle pulse wave velocity measurement/a survey of 12,517 subjects. Atherosclerosis, 166:303-9.
135. Vaitkevicius PV, Fleg JL, Engel JH, et al. 1993. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation, 88:1456-62.
136. Valverde AM, Mur C, Brownlee M, et al. 2004. Susceptibility to apoptosis in insulin-like growth factor-I receptor-deficient brown adipocytes. Mol Biol Cell, 15:5101-17.
137. Van Buul-Offers S, Ujeda I, Van den Brande JL. 1986. Biosynthetic somatomedin C increases the length and weight of Snell dwarf mice. Paediatric Res, 20:825-77.
138. Van Doornum S, McColl G, Wicks IP. 2004. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis, 63:1571-5.
139. Van Guldener C, Stehouwer CD. 2000. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost, 26:281-9.
140. Vincent AM, Maiese K. 1999. Nitric oxide induction of neuronal endonuclease activity in programmed cell death. Exp Cell Res, 246:290-300.
141. Wenn CM, Newman DL. 1990. Arterial tortuosity. Australas Phys Eng Sci Med, 13:67-70.
142. Westerbacka J, Wilkinson I, Cockcroft J, et al. 1999. Diminished wave reflection in the aorta: a novel physiological action of insulin on large blood vessels. Hypertension, 33:1118-22.
143. Wilkinson IB, Fuchs SA, Jansen IM, et al. 1998b. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens, 16:2079-84.
144. Wilkinson IB, Webb DJ, Cockcroft JR. 1999. Aortic pulse-wave velocity. Lancet, 354:1996-7.
145. Wilkinson IB, MacCallum H, Hupperetz PC, et al. 2001. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and nor-adrenaline in man. J Physiol, 530:541-50.
146. Wilkinson IB, Hall IR, MacCallum H, et al. 2002a. Pulse-wave analysis: clinical evaluation of a non-invasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol, 22:147-52.
147. Wilkinson IB, Quasem A, McEniery CM, et al. 2002b. Nitric oxide regulates local arterial distensibility in vivo. Circulation, 105:213-7.
148. Wit JM, Kooijman R, Rijkers GT, et al. 1993. Immunological findings in growth hormone treated patients. Hormone Res, 39:107-10.
149. Yaginuma T, Avolio A, O'Rourke MF. 1986. Effects of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. Circ Res, 20:153-60.
150. Yorek M, Leeney E, Dunlap J, et al. 1989. Effect of fatty acid composition on insulin and IGB-I binding in retinoblastoma cells. Invest Ophthalmol Vis Sci, 30:2087-92.